The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study

Atherosclerosis

Volumn 224, Issue 2, 2012, Pages 526-531

  Lopes Virella, Maria F ^a,b   Hunt, Kelly J ^a,b   Baker, Nathaniel L ^a   Virella, Gabriel ^c   Moritz, Thomas ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c Hines VA Cooperative Studies Program (CSP) Coordinating Center   (United States)

Author keywords

Biomarkers of plaque instability; Cardiovascular disease; Malondialdehyde modified LDL; Modified LDL capture assays; Modified LDL immune complexes; Myocardial infarction; Oxidized LDL; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AMPUTATION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DEATH; DISEASE COURSE; FEMALE; FOLLOW UP; GANGRENE; HEART INFARCTION; HUMAN; INCIDENCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STROKE;

ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INCIDENCE; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES; UP-REGULATION;

EID: 84866558847     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.08.006     Document Type: Article

References (29)

1. Ross R. Atherosclerosis - an inflammatory disease. N Eng J Med 1999, 340:115-126.
2. De Boer O.J., van der Wal A.C., Verhagen C.E., et al. Cytokin secretion profiles of cloned T cells from human aortic atherosclerotic plaques. J Pathol 1999, 188:174-179.
3. Hansson G.K., Jonasson L., Lojsthed B., et al. Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis 1988, 72:135-141.
4. Lundberg A.M., Hansson G.K. Innate immune signals in atherosclerosis. Clin Immunol 2010, 134:5-24.
5. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
6. Virella G., Lopes-Virella M.F. Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis 2008, 200:239-246.
7. Lopes-Virella M.F., Hunt K.J., Baker N.L., et al. The levels of oxidized LDL and AGE-LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes 2011, 60:582-589.
8. Virella G., Thorpe S., Alderson N.L., et al. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res 2004, 45:1859-1867.
9. Saad A.F., Virella G., Chassereau C., et al. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res 2006, 47:1975-1983.
10. Hammad S.M., Twal W.O., Barth J.L., et al. Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells. Atherosclerosis 2009, 202:394-404.
11. Kiener P.A., Rankin B.M., Davis P.M., et al. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler Thromb Vasc Biol 1995, 15:990-999.
12. Yla-Herttuala S., Palinski W., Rosenfeld M.E., et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989, 84:1086-1095.
13. Yla-Herttuala S., Palinski W., Rosenfeld M.E., et al. Lipoproteins in normal and atherosclerotic aorta. Eur Heart J 1990, 11:88-89.
14. Lopes-Virella M.F., McHenry M.B., Lipsitz S., et al. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 2007, 190:359-369.
15. Lopes-Virella M.F., Baker N.L., Hunt K.J., et al. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis 2011, 214:462-467.
16. Mironova M., Virella G., Lopes-Virella M.F. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol 1996, 16:222-229.
17. Abraira C., Duckworth W., McCarren M., et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complicat 2003, 17:314-322.
18. ADA Standards of medical care for patients with diabetes mellitus. Diabetes Care 2000, 23:S32-S64.
19. Virella G., Carter R.E., Saad A., et al. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol 2008, 127:394-400.
20. Virella G., Derrick M.B., Pate V., et al. Development of capture assays for different modifications of human low-density lipoprotein. Clin Diagn Lab Immunol 2005, 12:68-75.
21. Holvoet P., Perez G., Zhao Z., et al. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 1995, 95:2611-2619.
22. Holvoet P., Vanhaecke J., Janssens S., et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998, 98:1487-1494.
23. Lopes-Virella M.F., Binzafar N., Rackley S., et al. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis 1997, 135:161-170.
24. Oksjoki R., Kovanen P.T., Lindstedt K.A., et al. OxLDL-IgG immune complexes induce survival of human monocytes. Arterioscler Thromb Vasc Biol 2006, 26:576-583.
25. Holvoet P., Jenny N.S., Schreiner P.J., et al. The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007, 194:245-252.
26. Hulthe J., Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol 2002, 22:1162-1167.
27. Yamazaki K., Bujo H., Taira K., et al. Increased circulating malondialdehyde-modified LDL in the patients with familial combined hyperlipidemia and its relation with the hepatic lipase activity. Atherosclerosis 2004, 172:181-187.
28. Virella G., Lopes-Virella M.F. Lipoprotein autoantibodies: measurement and significance. Clin Diag Lab Immunol 2003, 10:499-505.
29. Koenig W., Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007, 27:15-26.